Novel method detects acetylcholinesterase activity in serum, indicating neurological disorder management.
Accurate detection of serum acetylcholinesterase (AChE) activity plays a crucial role in the clinical diagnosis and pharmacological treatment of neurological disorders. In this work, a novel method for determining serum AChE activity was developed based on the synergistically enhanced oxidase-mimicking activity of a Fe/Co single-atom nanozyme (Fe/Co–N/C). Fe/Co–N/C, featuring dual metal active sites, was successfully synthesized via high-temperature pyrolysis and demonstrated superior oxidase-like catalytic performance in the luminol-O2 chemiluminescence (CL) reaction compared to its single-atom counterparts. In the detection system, AChE specifically catalyzes the hydrolysis of acetylthiocholine chloride (ATCh) to release thiocholine, which acts as a potent reducing agent that scavenges reactive oxygen species (ROS) generated by Fe/Co–N/C in the presence of dissolved O2. Hence, the CL signal from the luminol–O2–Fe/Co–N/C system decreased significantly. The inhibition rate of the CL response exhibited a good linear relationship with AChE activity over the range of 0.025 to 10.0 mU/mL. The limit of detection (LOD, 3σ/S) was determined to be 8.3 μU/mL, with a relative standard deviation (RSD) of 2.7% at an AChE concentration of 0.5 mU/mL (n = 11). The proposed method was successfully applied to the determination of AChE activity in human serum samples. This study offers a promising alternative approach to support the clinical diagnosis and management of neurological diseases.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: